Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva

The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proceeds from the $35 million new financing transaction will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.